Bromomethane

Bromomethane

SCHEMBL223765

CBr.N#CCCC(Br)C#N

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
ALDH1A1 P00352 2/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5531904 0.95
Methane SCHEMBL2761950 0.92
SCHEMBL7159719 0.81
SCHEMBL7159813 0.77 TSHR (0.37) TSHRALDH1A1TDP1
SCHEMBL7164101 0.76 TSHR (0.47) TSHRALDH1A1
SCHEMBL6796953 0.72
SCHEMBL7691893 0.72
SCHEMBL27343568 0.71
SCHEMBL8932094 0.70
SCHEMBL28282352 0.70 TSHR (0.52) TSHRALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1023 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387489-A1 METHOD FOR PROVIDING A TOPICAL FORMULATION BASE PEEP CLUB LTD (GB) 2025-12-25 US claimed
US-20250332211-A1 COMPOSITIONS FOR INHIBITING DEGRADATION OF HYALURONIC ACID AND METHODS OF USE THEREOF EPIDARUS THERAPEUTICS LLC (US) 2025-10-30 US claimed
US-12370231-B2 Compositions for inhibiting degradation of hyaluronic acid and methods of use thereof EPIDARUS THERAPEUTICS, LLC (US) 2025-07-29 US claimed
WO-2024102364-A1 SYSTEM AND METHOD FOR REMOTE SCREENING AND DIAGNOSIS OF CONTACT ALLERGIES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-05-16 WO claimed
US-20240148635-A1 COSMETIC COMPOSITIONS COMPRISING POLYETHER POLYMERS P2 SCIENCE, INC. 2024-05-09 US claimed
US-11883453-B2 Formulation based on medicinal plant, or part or extract thereof, use of the formulation and product including said formulation PHYTOPLENUS BIOATIVOS S.A (BR) 2024-01-30 US claimed
US-11872300-B2 Cosmetic compositions comprising polyether polymers P2 SCIENCE, INC. (US) 2024-01-16 US claimed
US-20230363380-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2023-11-16 US claimed
WO-2023148531-A1 SMALL MOLECULES FOR USE IN PREVENTING AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES TOXFINDER, LDA (PT) 2023-08-10 WO claimed
WO-2023114999-A2 MOISTURIZER COMPOSITIONS AND METHODS OF MAKING THE SAME MOTAHARI ZAHRA (US) 2023-06-22 WO claimed
EP-1776156-A1 MICROPROJECTION APPARATUS AND SYSTEM WITH LOW INFECTION POTENTIAL Alza Corporation, c/o Johnson & Johnson (US) 2007-04-25 EP claimed
WO-2006044134-A2 TEMPORARY WET STRENGTH AGENTS AND PRODUCTS MADE FROM SUCH AGENTS LANXESS CORPORATION (US) 2006-04-27 WO claimed
WO-2006044116-A2 TEMPORARY WET STRENGTH AGENTS AND PRODUCTS MADE FROM SUCH AGENTS LANXESS CORPORATION (US) 2006-04-27 WO claimed
WO-2006020842-A1 MICROPROJECTION APPARATUS AND SYSTEM WITH LOW INFECTION POTENTIAL ALZA CORPORATION (US) 2006-02-23 WO claimed
US-20060034902-A1 Microprojection apparatus and system with low infection potential ALZA CORPORATION 2006-02-16 US claimed
US-20040247543-A1 Sunscreen compositions PLAYTEX PRODUCTS, INC. 2004-12-09 US claimed
US-20020028754-A1 Antimicrobial compositions NOVOZYMES A/S (DK) 2002-03-07 US claimed
WO-2002008377-A1 ANTIMICROBIAL COMPOSITIONS NOVOZYMES A/S (DK) 2002-01-31 WO claimed
US-6231849-B1 HUNTING Schiller, George A. 2001-05-15 US claimed
EP-0598412-A2 Skinprotection composition MEDICON GESELLSCHAFT FÜR UNTERNEHMENSBERATUNG IM BEREICH MEDIZIN UND GESUNDHEITSWESEN mbH (DE) 1994-05-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148635-A1 COSMETIC COMPOSITIONS COMPRISING POLYETHER POLYMERS CUTA, LAGE3, POLR1C TSHR 2071/4885ALDH1A1 364/4885TDP1 2078/4885
US-11872300-B2 Cosmetic compositions comprising polyether polymers CUTA, LAGE3, POLR1C TSHR 2071/4885ALDH1A1 364/4885TDP1 2078/4885
US-20250387489-A1 METHOD FOR PROVIDING A TOPICAL FORMULATION BASE VEGFA, AQP3, DSG1 TSHR 3688/4885ALDH1A1 4704/4885TDP1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.